Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AVRO

AVRO - Avrobio Inc Stock Price, Fair Value and News

1.29USD-0.01 (-0.77%)Market Closed
Watchlist

Market Summary

USD1.29-0.01
Market Closed
-0.77%

AVRO Stock Price

View Fullscreen

AVRO RSI Chart

AVRO Valuation

Market Cap

57.5M

Price/Earnings (Trailing)

-14.05

Price/Sales (Trailing)

79.97

Price/Free Cashflow

-0.73

AVRO Price/Sales (Trailing)

AVRO Profitability

Return on Equity

-3.98%

Return on Assets

-3.7%

Free Cashflow Yield

-137.11%

AVRO Fundamentals

AVRO Revenue

Revenue (TTM)

719.0K

Rev. Growth (Yr)

1.2K%

Rev. Growth (Qtr)

70.03%

AVRO Earnings

Earnings (TTM)

-4.1M

Earnings Growth (Yr)

6.06%

Earnings Growth (Qtr)

-131.98%

Breaking Down AVRO Revenue

Last 7 days

-2.3%

Last 30 days

-8.5%

Trailing 12 Months

-24.1%

How does AVRO drawdown profile look like?

AVRO Financial Health

Current Ratio

14.44

AVRO Investor Care

Shares Dilution (1Y)

1.83%

Diluted EPS (TTM)

-0.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210000
2020000719.0K

Tracking the Latest Insider Buys and Sells of Avrobio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 05, 2024
golipour azadeh
sold (taxes)
-14,698
1.2016
-12,232
chief technology officer
Feb 05, 2024
avruch steven
sold (taxes)
-12,996
1.202
-10,812
chief legal officer
Feb 05, 2024
ridha essra
sold (taxes)
-20,353
1.2006
-16,953
chief medical officer
Feb 05, 2024
ostrowski erik
sold (taxes)
-15,745
1.202
-13,099
interim ceo, president and cfo
Feb 01, 2024
avruch steven
acquired
-
-
32,834
chief legal officer
Feb 01, 2024
ostrowski erik
acquired
-
-
40,084
interim ceo, president and cfo
Feb 01, 2024
ridha essra
acquired
-
-
32,834
chief medical officer
Feb 01, 2024
golipour azadeh
acquired
-
-
37,334
chief technology officer
Jun 12, 2023
golipour azadeh
sold (taxes)
-6,634
1.1903
-5,574
chief technology officer
Jan 24, 2023
mackay geoffrey
acquired
41,859
0.91
45,999
president & ceo

1–10 of 31

Which funds bought or sold AVRO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
BARCLAYS PLC
unchanged
-
-3,000
24,000
-%
Feb 14, 2024
TANG CAPITAL MANAGEMENT LLC
sold off
-100
-5,409,540
-
-%
Feb 14, 2024
TWO SIGMA INVESTMENTS, LP
reduced
-5.61
-84,047
420,942
-%
Feb 14, 2024
BNP PARIBAS FINANCIAL MARKETS
unchanged
-
-539
4,072
-%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
added
62.81
99,386
326,382
0.01%
Feb 14, 2024
VANGUARD GROUP INC
added
1.71
-246,749
2,178,500
-%
Feb 14, 2024
Royal Bank of Canada
reduced
-4.35
-
3,000
-%
Feb 14, 2024
CITADEL ADVISORS LLC
added
1.03
-84,680
700,694
-%

1–10 of 44

Are Funds Buying or Selling AVRO?

Are funds buying AVRO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AVRO
No. of Funds

Unveiling Avrobio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
newtyn management, llc
6.1%
2,734,175
SC 13G
Feb 14, 2024
tang capital partners lp
0.0%
0
SC 13G/A
Feb 13, 2024
gmt capital corp
0.0%
0
SC 13G/A
Feb 07, 2024
bml investment partners, l.p.
9.0%
4,001,627
SC 13G/A
Jan 24, 2024
farallon capital partners, l.p.
0.0%
0
SC 13G/A
Jul 24, 2023
bml investment partners, l.p.
8.0%
3,545,396
SC 13G
Jun 06, 2023
tang capital partners lp
6.1%
2,705,000
SC 13G
Feb 17, 2023
farallon capital partners, l.p.
1.3%
563,900
SC 13G
Feb 08, 2023
k2 principal fund, l.p.
0.00%
10
SC 13G/A
Jan 19, 2023
gmt capital corp
2.9%
1,263,483
SC 13G/A

Recent SEC filings of Avrobio Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
S-4
Mergers and Acquisition
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Feb 05, 2024
4
Insider Trading
Jan 30, 2024
8-K
Current Report

Peers (Alternatives to Avrobio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Avrobio Inc News

Latest updates
Goodwin Procter01 Feb 202408:00 am
Business Wire30 Jan 202408:00 am

Avrobio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Revenue70.0%1,40782824818011184.0057.0029.002.009.00--
Operating Expenses34.1%21,09115,72925,22025,25722,98527,77429,41827,96232,62031,37526,88428,064
  S&GA Expenses36.7%6,2624,5817,8877,1207,0668,89710,1658,9629,5778,8318,3578,477
  R&D Expenses33.0%14,82911,14817,33318,13715,91918,87719,25319,00023,04322,54418,52719,587
Interest Expenses-100.0%-368463423374324304-----
Net Income-132.0%-21,57767,476-24,957-25,034-22,969-28,054-29,833-28,227-32,613-31,387-26,899-28,131
Net Income Margin25.4%-5.69*-7.63*-140.49*-147.27*-151.71*-165.13*-169.76*-165.68*-165.55*-171.34*-167.79*-166.50*
Free Cashflow-38.0%-20,223-14,652-20,292-23,673-16,501-29,255-28,046-26,747-25,091-21,194-27,454-30,569
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-17.4%11113483.00104129146175204216238246271233256270201217102117133143
  Current Assets-15.3%10912977.0010012614217119921223424226722925126519621498.00114130140
    Cash Equivalents-15.1%10612572.0093.0011613216219020122623326022024425818820690.00108127139
  Net PPE-100.0%-2.003.003.003.004.004.004.004.004.003.003.003.004.003.004.003.003.003.003.002.00
Liabilities-35.0%8.0012.0030.0029.0031.0028.0032.0034.0023.0017.0013.0017.0025.0016.0013.0015.0010.009.0011.0011.006.00
  Current Liabilities-35.2%8.0012.0014.0013.0016.0013.0017.0019.0023.0017.0013.0017.0025.0015.0013.0014.0010.009.0010.0011.005.00
Shareholder's Equity-15.7%10312253.0075.0098.0011814316919422123325420824025718620793.00107122137
  Retained Earnings-4.8%-468-446-514-489-464-441-413-383-355-322-291-264-236-199-170-144-122-104-88.84-71.74-55.72
  Additional Paid-In Capital0.4%571569567565562560557553549544524519444439427331329198196194193
Shares Outstanding0.6%45.0044.0044.0044.0044.0044.0044.0044.0044.0044.0042.0044.00---------
Float------34,838---337---534---289---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-38.0%-20,223-14,652-20,284-23,673-16,415-29,106-28,014-25,897-24,824-19,965-27,339-30,488-24,863-21,018-22,434-18,583-13,382-17,965-17,738-11,434-11,985
  Share Based Compensation44.7%2,2201,5342,5302,2552,6563,2333,3784,0855,1684,6914,6354,1024,8053,8992,8221,8851,7971,6631,4551,079551
Cashflow From Investing-98.6%1,19883,736-8.00--86.00-149-32.00-850-267-1,229-115-81.00-31.00-488-577-766-78.00-401-340-234-1,198
Cashflow From Financing101.1%178-16,32155.0059.0060.001.0014214,94522.0014,60579970,70560.008,19193,66330.00129,474238252-139-3,255

AVRO Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 14,829$ 15,919$ 43,310$ 54,049
General and administrative6,2627,06618,73026,128
Total operating expenses21,09122,98562,04080,177
Gain on asset sale0083,7360
Loss on impairment(1,842)0(1,842)0
(Loss) Income from operations(22,933)(22,985)19,854(80,177)
Other (expense) income:    
Interest income (expense), net1,4071111,160(544)
Other expense, net(51)(95)(72)(135)
Total other income (expense), net1,356161,088(679)
Net income (loss) and comprehensive income (loss) attributable to common stockholders - basic and diluted$ (21,577)$ (22,969)$ 20,942$ (80,856)
Net income (loss) per share applicable to common stockholders basic$ (0.48)$ (0.52)$ 0.47$ (1.85)
Net income (loss) per share applicable to common stockholders diluted$ (0.48)$ (0.52)$ 0.47$ (1.85)
Weighted-average common shares outstanding basic44,527,99743,772,99044,234,93643,722,129
Weighted-average common shares outstanding-diluted44,527,99743,772,99044,425,53143,722,129

AVRO Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 105,842$ 92,563
Restricted cash283283
Prepaid expenses and other current assets2,8607,112
Held for sale assets1850
Total current assets109,17099,958
Operating lease assets9121,057
Property and equipment, net02,894
Restricted cash, net of current portion4000
Other assets4040
Total assets110,522103,949
Current liabilities:  
Accounts payable910384
Accrued expenses and other current liabilities5,00211,732
Operating lease liabilities1,647999
Total current liabilities7,55913,115
Note payable, net of discount015,276
Operating lease liabilities, net of current portion105188
Total liabilities7,66428,579
Commitments and contingencies (Note 7)
Stockholders’ equity:  
Common stock, $0.0001 par value; 150,000 shares authorized; 44,580 and 43,916 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively44
Additional paid-in capital571,344564,798
Accumulated deficit(468,490)(489,432)
Total stockholders’ equity102,85875,370
Total liabilities and stockholders’ equity$ 110,522$ 103,949
AVRO
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
 WEBSITEwww.avrobio.com
 EMPLOYEES78

Avrobio Inc Frequently Asked Questions


What is the ticker symbol for Avrobio Inc? What does AVRO stand for in stocks?

AVRO is the stock ticker symbol of Avrobio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avrobio Inc (AVRO)?

As of Thu Feb 22 2024, market cap of Avrobio Inc is 57.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVRO stock?

You can check AVRO's fair value in chart for subscribers.

What is the fair value of AVRO stock?

You can check AVRO's fair value in chart for subscribers. The fair value of Avrobio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avrobio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avrobio Inc a good stock to buy?

The fair value guage provides a quick view whether AVRO is over valued or under valued. Whether Avrobio Inc is cheap or expensive depends on the assumptions which impact Avrobio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVRO.

What is Avrobio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AVRO's PE ratio (Price to Earnings) is -14.05 and Price to Sales (PS) ratio is 79.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVRO PE ratio will change depending on the future growth rate expectations of investors.